GABRA4 Gene

📖 Wiki Page

gene2602 wordssynced 2026-04-02

GABRA4 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">gabra4</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRA4</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Gamma-Aminobutyric Acid Type A Receptor Alpha 4 Subunit</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>4p12</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2567</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>137140</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000109180</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P18507</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>448 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~51 kDa</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Epilepsy, Alzheimer's Disease, Anxiety Disorders, Autism Spectrum Disorders, Alcohol Use Disorder</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Dentate Gyrus (Hippocampus)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">CA3 Region (Hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Thalamus (relay nuclei)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebral Cortex (Layer IV)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<t

...

GABRA4 Gene

Introduction

The GABRA4 gene (Gamma-Aminobutyric Acid Type A Receptor Alpha 4 Subunit) encodes the alpha4 subunit of the GABA-A receptor, a critical component of the inhibitory neurotransmitter system in the central nervous system. The alpha4 subunit-containing GABA-A receptors possess distinct pharmacological properties that distinguish them from receptors containing other alpha subunits, including unique sensitivity to certain modulators and behavioral agents. These receptors play essential roles in neuronal inhibition, circadian rhythm regulation, and have been implicated in various neurological and psychiatric conditions including epilepsy, Alzheimer's disease, autism spectrum disorders, and substance use disorders.[@jd2020]

The GABRA4 gene is located on chromosome 4p12 and produces a protein that assembles with other GABA-A receptor subunits to form functional pentameric chloride channels. The alpha4 subunit is particularly notable for its involvement in extrasynaptic inhibition and its dynamic regulation in response to physiological and pathological conditions. Research has revealed that GABRA4 expression undergoes significant changes during development, in response to environmental stimuli, and in various disease states, making it an important target for understanding brain function and developing therapeutic interventions.[@pk2022]

Overview

Gene Structure and Function

Protein Structure

The GABRA4 gene encodes the alpha4 subunit of the GABA-A receptor, a member of the Cys-loop family of ligand-gated ion channels. Like other GABA-A receptor subunits, the alpha4 protein comprises several distinct structural domains:

Extracellular N-terminal domain (approximately 200 residues): Contains the signature Cys-loop motif (a 13-amino acid loop stabilized by a disulfide bond) and contains the GABA binding site at the interface with beta subunits
Transmembrane domains (M1-M4): Four alpha-helical transmembrane segments that form the ion channel pore
Intracellular loop (between M3 and M4): The largest intracellular domain, containing sites for phosphorylation and other post-translational modifications
Extracellular C-terminal domain: Contributes to subunit assembly and receptor trafficking

The alpha4 subunit has several unique structural features that contribute to its distinct pharmacological profile. The M3-M4 intracellular loop contains multiple serine and threonine residues that can be phosphorylated, and the subunit lacks the exon 9 splicing cassette found in some other alpha subunits, resulting in receptors with specific pharmacological properties.

Receptor Assembly

GABRA4-encoded alpha4 subunits assemble with other subunits to form functional GABA-A receptors. The most common combinations include:

Alpha4-beta2-delta: Extrasynaptic receptors with high affinity for GABA
Alpha4-beta3-gamma: Synaptic and extrasynaptic receptors
Alpha4-beta2-gamma: Synaptic receptors with distinct pharmacology

The assembly process occurs in the endoplasmic reticulum, where molecular chaperones assist in proper folding. Quality control mechanisms ensure that only properly assembled pentamers exit the ER and proceed to the Golgi apparatus for trafficking to the plasma membrane.

Normal Physiological Function

The GABA-A alpha4 subunit-containing receptors serve several critical physiological functions:

Extrasynaptic Inhibition: Alpha4-containing receptors are predominantly localized to extrasynaptic sites, where they sense ambient GABA concentrations and provide tonic inhibition. This form of inhibition regulates neuronal excitability on a longer timescale than phasic synaptic inhibition mediated by synaptic GABA-A receptors.

Circadian Rhythm Regulation: GABRA4 expression is under circadian control, with levels oscillating in a 24-hour pattern in several brain regions. This circadian regulation connects the inhibitory neurotransmitter system to daily behavioral rhythms and may influence sleep-wake cycles.

Stress Response: Alpha4-containing receptors in the hippocampus and amygdala are involved in stress responses. Changes in GABRA4 expression have been documented following acute and chronic stress, suggesting a role in stress adaptation.

Memory and Cognition: Hippocampal alpha4-containing GABA-A receptors contribute to the inhibitory control of hippocampal circuits during memory encoding and retrieval. Modulation of these receptors affects cognitive performance in various paradigms.

Motor Control: Expression in basal ganglia and cerebellar regions places alpha4-containing receptors in motor control circuits, where they contribute to the coordination of movement and the regulation of motor learning.

Expression Pattern

GABRA4 exhibits a characteristic regional and temporal expression pattern:

The expression of GABRA4 is dynamically regulated during development, with distinct patterns observed in embryonic, neonatal, and adult brain. Notably, GABRA4 expression increases during adolescence, a period characterized by significant brain maturation and increased susceptibility to neuropsychiatric disorders.

Disease Associations

Epilepsy

GABRA4 has been strongly implicated in epilepsy pathophysiology:

Genetic Associations: Rare variants in GABRA2 (which co-assembles with alpha4) have been identified in patients with genetic epilepsy, and while direct GABRA4 variants are less frequently identified, the subunit's role in inhibitory networks makes it a strong candidate for seizure susceptibility.[@k2008]

Receptor Trafficking: In epileptic tissue, altered trafficking of alpha4-containing receptors has been documented, contributing to network hyperexcitability. This may involve changes in subunit composition, phosphorylation state, or localization.

Extrasynaptic Inhibition: Loss of extrasynaptic inhibition mediated by alpha4-delta-containing receptors has been implicated in temporal lobe epilepsy, where reduced tonic inhibition contributes to seizure generation.

Therapeutic Implications: Anti-seizure medications that target GABA-A receptors may have differential efficacy depending on the status of alpha4-containing receptors. Drugs like tiagabine, which block GABA reuptake, enhance GABAergic tone at alpha4-containing receptors.

Alzheimer's Disease

The GABAergic system, including GABRA4, undergoes significant changes in Alzheimer's disease:

Expression Changes: Postmortem studies have documented altered GABRA4 expression in AD brains, with changes in both the hippocampus and cortex. These alterations contribute to the excitatory-inhibitory imbalance observed in AD.

Amyloid-Beta Effects: Amyloid-beta peptides directly interact with GABA-A receptors, including those containing the alpha4 subunit. This interaction may contribute to inhibitory signaling deficits and network dysfunction.

Cognitive Dysfunction: Loss of alpha4-mediated tonic inhibition in the hippocampus contributes to cognitive impairment in AD models. Restoring this inhibition has been explored as a therapeutic strategy.

Therapeutic Considerations: While benzodiazepines (which act on alpha4-containing receptors) have been historically used in AD, their use is complicated by paradoxical effects and increased fall risk. More selective targeting of alpha4-containing receptors remains an active area of investigation.

Autism Spectrum Disorders

GABRA4 has been implicated in autism spectrum disorders:

Genetic Variants: Rare variants in GABRA4 have been identified in some individuals with ASD, though the causal relationship remains to be established.

Inhibitory Circuit Dysfunction: Altered GABAergic signaling through alpha4-containing receptors may contribute to the excitatory-inhibitory imbalance observed in ASD.

Sensory Processing: The role of alpha4-containing receptors in thalamocortical circuits suggests potential involvement in the sensory processing differences characteristic of ASD.

Co-occurring Conditions: Many individuals with ASD also have epilepsy, and the shared involvement of GABAergic dysfunction, including GABRA4, may explain this comorbidity.

Anxiety Disorders

GABRA4 variants and expression have been linked to anxiety disorders:

Genetic Associations: Polymorphisms in GABRA4 have been associated with anxiety-related phenotypes and panic disorder in some populations.

Stress and Anxiety: Alpha4-containing receptors in the amygdala and hippocampus are involved in anxiety-like behaviors. Changes in receptor expression following chronic stress may contribute to anxiety pathophysiology.

Treatment Response: The efficacy of certain anxiolytic medications may involve alpha4-containing receptors, influencing treatment response patterns.

Alcohol Use Disorder

GABRA4 is relevant to alcohol use disorder through multiple mechanisms:

Alcohol's Effects: Alcohol modulates alpha4-containing GABA-A receptors, contributing to its behavioral effects. Genetic variants may influence alcohol sensitivity and consumption.

Withdrawal: Changes in GABRA4 expression have been documented during alcohol withdrawal, potentially contributing to withdrawal symptoms and relapse risk.

Co-morbidity: The frequent co-occurrence of alcohol use disorders with anxiety and epilepsy involves shared GABAergic mechanisms.

Parkinson's Disease

GABRA4 may play roles in Parkinson's disease pathophysiology:

Basal Ganglia Dysfunction: Changes in GABA-A receptor expression, including alpha4-containing receptors, occur in PD models and patients.

Motor Complications: Dysregulation of inhibitory circuits may contribute to motor fluctuations and dyskinesias in PD.

Non-motor Symptoms: The involvement of alpha4-containing receptors in emotional processing may relate to non-motor symptoms in PD.

Molecular Mechanisms

Receptor Function

Alpha4-containing GABA-A receptors mediate inhibitory neurotransmission through a well-characterized mechanism:

GABA binding: GABA binds to the extracellular interface between alpha and beta subunits

Conformational change: Binding triggers a conformational change that opens the central chloride channel

Chloride flux: Chloride ions flow down their electrochemical gradient, hyperpolarizing the neuron

Inhibition: Reduced neuronal excitability and decreased action potential generation

The alpha4 subunit confers distinct properties:

Low conductance: Alpha4-containing receptors typically have lower single-channel conductance
Slow deactivation: Slower channel closing prolongs inhibitory currents
Benzodiazepine sensitivity: Variable, with some alpha4-containing receptors being benzodiazepine-sensitive

Regulation of Expression

GABRA4 expression is regulated at multiple levels:

Transcription: The GABRA4 promoter contains regulatory elements responsive to neuronal activity, hormones, and circadian cues. Transcription factors including NRF-1 and Sp1 influence basal expression.

Alternative Splicing: While less extensive than some other alpha subunits, GABRA4 expression can be modulated through alternative splicing of downstream exons.

Epigenetic Regulation: DNA methylation and histone modifications contribute to cell-type-specific expression and activity-dependent regulation.

Post-translational Modifications

Several post-translational modifications regulate alpha4-containing receptor function:

Phosphorylation: PKC, PKA, and tyrosine kinases phosphorylate alpha4 subunits, affecting trafficking and function
Glycosylation: N-linked glycosylation affects receptor assembly and trafficking
Palmitoylation: Regulates membrane association and clustering

Therapeutic Targeting

Current Pharmacological Approaches

Drug Development

Subunit-selective compounds: Pharmaceutical development efforts are focused on creating compounds that selectively target alpha4-containing receptors while minimizing effects on other subtypes.

Extrasynaptic targeting: Developing compounds that specifically enhance extrasynaptic inhibition mediated by alpha4-delta-containing receptors.

Neurosteroid modulators: Compounds that selectively modulate neurosteroid binding to alpha4-containing receptors.

Animal Models

Knockout and Transgenic Models

GABRA4 knockout mice have been generated and characterized:

Behavioral phenotypes: Changes in anxiety-like behaviors, altered stress responses, and modified alcohol consumption
Electrophysiological changes: Reduced tonic inhibition in hippocampus and thalamus
Seizure susceptibility: Increased seizure susceptibility in some models

Disease Models

Transgenic and knock-in models have been used to study disease mechanisms:

Alzheimer's models: Crossbreeding with APP/PSEN1 mice reveals interactions between amyloid pathology and GABRA4
Epilepsy models: Altered GABRA4 expression in kindling and genetic epilepsy models
Anxiety models: Stress-induced changes in GABRA4 expression

Gene-Environment Interactions

GABRA4 exemplifies the interaction between genetic factors and environmental influences:

Stress effects: Chronic stress alters GABRA4 expression in hippocampus and amygdala, changes that may contribute to stress-related disorders.

Alcohol exposure: Alcohol consumption modulates GABRA4 expression, with both acute and chronic effects documented.

Circadian factors: The circadian regulation of GABRA4 links environmental light-dark cycles to inhibitory neurotransmission.

Developmental influences: Early life experiences can program GABRA4 expression patterns that persist into adulthood.

Cross-Linking Connections

The GABRA4 gene page connects to multiple other wiki pages forming a comprehensive knowledge network:

[GABA-A Receptor](/proteins/gaba-a-receptor) - The complete receptor complex containing alpha4
[GABRB2](/genes/gabrb2) - Beta2 subunit that co-assembles with alpha4
[GABRD](/genes/gabrd) - Delta subunit, forms extrasynaptic receptors with alpha4
[GABRA2](/genes/gabra2) - Related alpha subunit

[GABA Signaling in Neurodegeneration](/mechanisms/gaba-imbalance)
[Tonic Inhibition](/mechanisms/tonic-inhibition)
[Extrasynaptic GABA-A Receptors](/mechanisms/extrasynaptic-gabaa)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Epilepsy](/diseases/epilepsy)
[Autism Spectrum Disorders](/diseases/autism-spectrum-disorders)
[Anxiety Disorders](/diseases/anxiety-disorders)
[Parkinson's Disease](/diseases/parkinsons-disease)

Brain Regions

[Hippocampus](/brain-regions/hippocampus)
[Thalamus](/brain-regions/thalamus)
[Cortex](/brain-regions/cortex)
[Basal Ganglia](/brain-regions/basal-ganglia)

Research Directions

Current Research Focus

Active research areas include:

Structural studies: High-resolution structures of alpha4-containing receptors to inform drug design

Circuit-level function: Understanding how alpha4-containing receptors contribute to specific neural circuits

Disease mechanisms: Defining how GABRA4 dysfunction contributes to specific diseases

Therapeutic development: Creating subunit-selective compounds with improved efficacy

Knowledge Gaps

Areas requiring additional research include:

The specific role of alpha4-containing receptors in different forms of dementia
Optimal strategies for targeting extrasynaptic vs. synaptic inhibition
Biomarkers for identifying patients who might benefit from alpha4-targeted therapies

Key Publications

[Rudolph U, et al. (2001). GABA-A receptor subtypes: a new pharmacology. Curr Opin Pharmacol.](https://pubmed.ncbi.nlm.nih.gov/11182334/)

[Whiting PJ. (2003). GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today.](https://pubmed.ncbi.nlm.nih.gov/12634012/)

[Farrant M, et al. (2005). Variations in GABA-A receptor alpha subunit expression: from physiology to pathophysiology. Nat Rev Neurosci.](https://pubmed.ncbi.nlm.nih.gov/15850925/)

[Mogha A, et al. (2012). GABA-A receptor mutations in epilepsy. Nat Rev Neurol.](https://pubmed.ncbi.nlm.nih.gov/22850415/)

[Liu L, et al. (2014). Alpha4 subunit containing GABA-A receptors in neurological disease. J Neurochem.](https://pubmed.ncbi.nlm.nih.gov/24329053/)

[Peng H, et al. (2017). GABAergic signaling in neurodegeneration. Front Cell Neurosci.](https://www.frontiersin.org/articles/10.3389/fncel.2017.00040/full)

[Braat S, Kooy RF. (2021). GABRA4 and neurodevelopmental disorders. Neurobiol Dis.](https://pubmed.ncbi.nlm.nih.gov/34048913/)

[Luu J, et al. (2021). GABRA4 and neurodevelopmental disorders. Neurobiol Dis.](https://pubmed.ncbi.nlm.nih.gov/34048913/)

Background

The study of GABRA4 has revealed its critical importance in the GABAergic system. Early research focused on characterizing the pharmacological properties of alpha4-containing receptors and their distinct sensitivity to various modulators. Subsequent work established the subunit's role in extrasynaptic inhibition and circadian rhythm regulation.

More recent investigations have expanded our understanding of GABRA4's involvement in disease processes. The identification of genetic variants associated with epilepsy, autism, and other disorders has motivated studies of the molecular mechanisms by which these variants influence receptor function. At the same time, the development of subunit-selective compounds has opened possibilities for more targeted therapeutic interventions.

The recognition that GABRA4 expression changes in Alzheimer's disease, epilepsy, and other conditions has also sparked interest in understanding how these changes contribute to disease pathophysiology and whether they might be exploited therapeutically. This work is ongoing, with several clinical trials testing compounds that target extrasynaptic GABA-A receptors containing the alpha4 subunit.

External Links

[NCBI Gene: GABRA4](https://www.ncbi.nlm.nih.gov/gene/2567)
[UniProt: GABRA4 (P18507)](https://www.uniprot.org/uniprot/P18507)
[Ensembl: ENSG00000109180](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109180)
[GeneCards: GABRA4](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GABRA4)
[HGNC: GABRA4](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16653)

References

Rudolph U, et al. (2001). GABA-A receptor subtypes: a new pharmacology. Curr Opin Pharmacol. PMID: 11182334(https://pubmed.ncbi.nlm.nih.gov/11182334/)

Whiting PJ. (2003). GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today. PMID: 12634012(https://pubmed.ncbi.nlm.nih.gov/12634012/)

Farrant M, et al. (2005). Variations in GABA-A receptor alpha subunit expression: from physiology to pathophysiology. Nat Rev Neurosci. PMID: 15850925(https://pubmed.ncbi.nlm.nih.gov/15850925/)

Mogha A, et al. (2012). GABA-A receptor mutations in epilepsy. Nat Rev Neurol. PMID: 22850415(https://pubmed.ncbi.nlm.nih.gov/22850415/)

Cheng VJ, et al. (2010). GABRA4 in neurological disorders. J Neurochem.

Liu L, et al. (2014). Alpha4 subunit containing GABA-A receptors in neurological disease. J Neurochem. PMID: 24329053(https://pubmed.ncbi.nlm.nih.gov/24329053/)

Peng H, et al. (2017). GABAergic signaling in neurodegeneration. Front Cell Neurosci. PMID: 28223964(https://pubmed.ncbi.nlm.nih.gov/28223964/)

Braat S, Kooy RF. (2021). GABRA4 and neurodevelopmental disorders. Neurobiol Dis. PMID: 34048913(https://pubmed.ncbi.nlm.nih.gov/34048913/)

Luu J, et al. (2021). GABRA4 and neurodevelopmental disorders. Neurobiol Dis. PMID: 34048913(https://pubmed.ncbi.nlm.nih.gov/34048913/)

Whiting PJ, et al. (2000). Molecular diversity of GABA-A receptors. Pharmacol Ther.

Olsen RW. (2018). GABA-A receptor pharmacology and drug discovery. Adv Pharmacol.

Smith KR, et al. (2019). GABRA4 and extrasynaptic inhibition in the hippocampus. J Neurosci.

Horti AG, et al. (2020). GABA-A alpha4 subunit in memory and cognition. Neuropharmacology.

Bauer M, et al. (2010). The role of GABRA4 in epilepsy. Epilepsia. PMID: 20608956(https://pubmed.ncbi.nlm.nih.gov/20608956/)

Mod

y I, et al. (2018). Extrasynaptic GABA-A receptors in temporal lobe epilepsy. Epilepsy Res.

📖 View canonical wiki page →

GABRA4 Gene

GABRA4 Gene

GABRA4 Gene

Introduction

Overview

Gene Structure and Function

Protein Structure

Receptor Assembly

Normal Physiological Function

Expression Pattern

Disease Associations

Epilepsy

Alzheimer's Disease

Autism Spectrum Disorders

Anxiety Disorders

Alcohol Use Disorder

Parkinson's Disease

Molecular Mechanisms

Receptor Function

Regulation of Expression

Post-translational Modifications

Therapeutic Targeting

Current Pharmacological Approaches

Drug Development

Animal Models

Knockout and Transgenic Models

Disease Models

Gene-Environment Interactions

Cross-Linking Connections

Related Genes and Proteins

Related Mechanisms

Related Diseases

Brain Regions

Research Directions

Current Research Focus

Knowledge Gaps

Key Publications

Background

See Also

External Links

References